CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • MESO Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit
  • 6-K Filing

Mesoblast (MESO) 6-KRemestemcel-L reduced mortality through 60 days in the pre-specified population under 65 years old

Filed: 3 May 21, 6:04am
Free signup for more
  • Track your favorite companies
  • Receive email alerts for new filings
  • Personalized dashboard of news and more
  • Access all data and search results
Sign up for free
Search this filing
?
Pre-defined:
Table of contents
    Filing tables
    Export all tables to Excel
    Filing exhibits
    SEC
    • 6-K Current report (foreign)
    • 99.1 Additional exhibits
    • 99.2 Additional exhibits
    MESO similar filings
    • 4 Jun 21 Current report (foreign)
    • 4 Jun 21 Current report (foreign)
    • 27 May 21 Improved Outcomes In Inflammatory Lung Disease with Remestemcel-l Published In Respiratory Research Journal
    • 3 May 21 Remestemcel-L reduced mortality through 60 days in the pre-specified population under 65 years old
    • 8 Apr 21 Current report (foreign)
    • 1 Apr 21 Mesoblast Operational Highlights and Upcoming Milestones
    • 30 Mar 21 Philip J. Facchina, Chief Strategy Officer and Principal of Surgcenter Development, Joins Mesoblast Board
    Filing view
    Share this filing

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     Form 6-K

    Report of Foreign Private Issuer
    Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

    For the month of April 2021

    Commission File Number 001-37626

    Mesoblast Limited

    (Exact name of Registrant as specified in its charter)

    Not Applicable

    (Translation of Registrant’s name into English)

    Australia
    (
    Jurisdiction of incorporation or organization)

     

    Silviu Itescu

    Chief Executive Officer and Executive Director

    Level 38

    55 Collins Street

    Melbourne 3000

    Australia

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

    Form 20-F ☑ Form 40-F ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

    Yes ☐ No ☑

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

    Yes ☐ No ☑

     


     

    INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

    On April 30, 2021, Mesoblast Limited filed with the Australian Securities Exchange a new release announcement, which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

    On April 30, 2021, Mesoblast Limited filed with the Australian Securities Exchange a quarterly report for entities admitted on the basis of commitments (Appendix 4C) for the quarter ended March 31, 2021, which is attached hereto as Exhibit 99.2, and is incorporated herein by reference.



     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

     

     

     

     

     

     

     

     

    Mesoblast Limited

     

     

     

     

     

     

    /s/ Charlie Harrison

     

     

     

     

     

     

     

     

     

    Charlie Harrison

     

     

     

     

    Company Secretary

     

     

     

    Dated: May 3, 2021


     

    INDEX TO EXHIBITS

     

     

     

    Item

     

     

     

     

     

    99.1

     

    Press release of Mesoblast Ltd, dated April 30, 2021.

    99.2

     

    Appendix 4C of Mesoblast Ltd, dated April 30, 2021.

     

     

     

     

     

     

    Finsight
    Resources
    • Knowledgebase
    • Log In
    • Register
    Company
    • About
    • Contact
    • Solutions
    Products
    • Deal Roadshow
    • DealVDR
    • Evercall
    • Finsight.com
    CapEdge
    • Earnings Calendar
    • Earnings Transcripts
    • EDGAR Filing Screener
    • IPO Calendar
    • Compliance
    • Privacy
    • Security
    • Terms
    AngelList LinkedIn